What Wall Street is seeing as market rally begins to stall out
US stock futures (ES=F, NQ=F, YM=F) pull back in Wednesday pre-market trading while bond yields (^TYX, ^TNX, ^FVX) continue to rise as the market rally seems to be stalling.
Yahoo Finance senior markets reporter Josh Schafer comes on The Morning Brief to share his snapshot of the US stock market (^DJI, ^IXIC, ^GSPC), citing EY chief economist Gregory Daco's note that equities have "reacted with unwarranted optimism, overlooking the persistent economic drag posed by elevated tariffs."
To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Challenges pharma companies face in push into US manufacturing
Yahoo Finance senior health reporter Anjalee Khemlani explains the pharmaceutical industry's push into domestic manufacturing in the US, as a reshoring tactic to tighten up the supply chain. Planning can still take several years to be finalized and face cost barriers amid tariffs. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Well, the pharmaceutical industry has its eye on US-based manufacturing. What does that mean near term for the sector? Yahoo Finance's Anjali Comlani joins us now with more on obviously there's been a big push in many different industries to reshore manufacturing. Um, pharmaceutical companies seem pretty much on board with this, but what does it look like in actuality? Well, it actually is that they're on board and they have been, but not for the reasons that have anything to do with tariffs. This is not something new for them. Really, the pharma industry has been pushing for reshoring since the COVID-19 pandemic. And that's because that's when they first learned of the risk of the supply chain. So what we have now is this like grand big number, 270 billion plus in investment dollars that has been announced by some of the major companies in the last few months. And that is because of projects that have already been on the table or new projects that they may have pushed up the launch for announcement for in light of the Trump administration pressuring with tariffs and the threat of tariffs. The idea being that if they commit to these reshoring projects, then they will somehow get out of the tariffs. Now, that doesn't seem to be panning out. We know that the Trump administration has said that they will be announcing some sort of tariff soon. So all eyes on that, and what that means then for these companies, will they continue to commit? Will they slow down the pace of them? We're going to sit there and and and wait for them to tell us. But in the meantime, just take a look at the pros and cons of what this reshoring really looks like. On the pro side, you have a majority of drugs currently being produced in Europe and Asia. Europe takes the branded and Asia really for the generics. Now, US really uses a lot of generic drugs, so a lot of our reliance is on Asia for that reason. As I mentioned, COVID-19 showed us that the supply chain is at risk, and so bringing it back will help us with that. Also, newer medications, personalized medications, need to be closer to home. And that's one of the reasons why these companies were already focused on reshoring, or rather opening plants here, because there are some newer medications that have maybe shorter shelf lives or need to be closer to the patient. Um, it's just an easier process. Meanwhile, these companies are also looking at patent cliffs. And that's something that would help boost more manufacturing because they need to focus on their R&D pipeline, and that requires more manufacturing for dosing for clinical trials and the like. Now, looking at the disadvantages, uh, costs are up at this current time in part, thanks to tariffs on some of the construction material. Also, the construction area specifically for manufacturing for pharma, they are facing labor shortages and some of them is getting disrupted by immigration. So that's stressing the sector and means that any of these projects could hit snags and pauses. There's also the pressure from the inflation reduction Act and the most favored nations clauses, and how much price absorption the company is has to do, the companies will have to deal with there. Meanwhile, also, the planning takes about three to five years. So if they're looking at rolling out these plans by 2030, um, they should really be on it right about now to make that happen. I also want to talk about, um, some of the areas. One really interesting thing that is happening though with this shift and this focus is I want to take a look at this map right now, which has sort of these established hubs for pharma manufacturing. You know that the West Coast and California, um, as well as the East Coast, North Carolina, that research triangle, New York, New Jersey area, as well as Boston, has been major hub. Texas and Ohio are coming up interestingly enough, as well as a little bit of South Carolina tied to North Carolina, and then Indianapolis. That one's interesting to me because that is all and entirely Eli Lilly. Thanks to the JLP1. So we're seeing some more interest in some different areas. So what I'm interested in seeing is how much that really appeases the Trump administration, which wants to bring back, you know, manufacturing at large, and will it actually succeed in doing that for this industry? That's the question. Yeah. All right. Thank you, Ange. Appreciate it.
Yahoo
6 hours ago
- Yahoo
If You Invested $10K In AvalonBay Communities Stock 10 Years Ago, How Much Would You Have Now?
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. AvalonBay Communities Inc. (NYSE:AVB) is a multifamily real estate investment trust, which develops, redevelops, acquires, and manages distinctive communities in select U.S. markets. The company's stock traded at approximately $161.01 per share 10 years ago. If you had invested $10,000, you could have bought roughly 62 shares. Currently, shares trade at $203.96, meaning your investment's value could have grown to $12,668 from stock price appreciation alone. However, AvalonBay Communities also paid dividends during these 10 years. Don't Miss: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Invest Where It Hurts — And Help Millions Heal: AvalonBay Communities' dividend yield is currently 3.43%. Over the last 10 years, it has paid about $64.02 in dividends per share, which means you could have made $3,976 from dividends alone. Summing up $12,668 and $3,976, we end up with the final value of your investment, which is $16,644. This is how much you could have made if you had invested $10,000 in AvalonBay Communities stock 10 years ago. This means a total return of 66.44%. However, this figure is significantly less than the S&P 500 total return for the same period, which was 238.30%. AvalonBay Communities has a consensus rating of "Neutral" and a price target of $221.59 based on the ratings of 25 analysts. The price target implies more than 8% potential upside from the current stock price. Trending: If there was a new fund backed by Jeff Bezos offering a ? On April 30, the company announced its Q1 2025, posting FFO of $2.83, compared to the consensus estimate of $2.81, and revenues of $745.88 million, compared to the consensus of $743.17 million, as reported by Benzinga. The company provided its Q2 2025 guidance, expecting core FFO per share in the range of $2.72 to $2.82, and EPS of $1.78 to $1.88. Check out this article by Benzinga for eight analysts' insights on AvalonBay Communities. Given the expected upside potential, growth-focused investors may find AvalonBay Communities stock attractive. Furthermore, they can benefit from the company's solid dividend yield of 3.43%. Read Next: Maximize saving for your retirement and cut down on taxes: . , which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum. Image: Shutterstock This article If You Invested $10K In AvalonBay Communities Stock 10 Years Ago, How Much Would You Have Now? originally appeared on Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
18 hours ago
- Yahoo
This Bitcoin Trader Went From A $1 Billion Long Position To Begging For Donations
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. "James Wynn" has dominated conversations on cryptocurrency Twitter for risky Bitcoin bets. Wynn appeared unstoppable at first, but his victory lap was brief. The high-risk trader is not yet willing to throw in the towel. A popular saying goes, 'Quit while you're ahead.' For "James Wynn," however, this likely means nothing. The pseudonymous cryptocurrency trader who rose to prominence for catching Pepe early in 2023 grabbed headlines in May for a $1 billion long bet on Bitcoin on the decentralized exchange Hyperliquid, using 40x leverage. What could go wrong? Well... everything. But it was not apparent at first. Don't Miss: — no wallets, just price speculation and free paper trading to practice different strategies. Grow your IRA or 401(k) with Crypto – . At first, it seemed like the market could not go against Wynn. Bitcoin surged to record highs above $110,000 and Wynn's unrealized profit swelled to $100 million. 'People see the trades and think it's some high-level stupid gambling kind of thing, and yes it is,' Wynn said at the time. 'But it is backed by my own thesis, which in turn, is a calculated risk.' Wynn doubled down by opening similar leverage positions on memecoins like Pepe, TRUMP and FARTCOIN, betting that Bitcoin would go higher. 'Bitcoin is dying to breakout higher. My target remains the same of 115-118k by the end of next week. However, could easily happen within a matter of hours even,' he said. But this prediction failed to materialize. Bitcoin instead began to retreat from its highs and Wynn's high-risk positions unraveled spectacularly, turning a $100 million paper profit into a $17.5 million total account loss. Trending: New to crypto? on Coinbase. 'I've decided to give perp trading a break,' Wynn said in the aftermath. 'Its been a fun ride. Approx $4m into $100m and then back down to a total account loss of $17,500,000. The time has come for me to return to where I came from. The place that helped carve me into the gigantic degenerate I'am today.' Wynn's hiatus did not last long. He was back on Monday asking his followers for donations to 'fight the market making cabal,' promising full refunds, presumably after beating this supposed cabal. It is unclear what victory in this fight will look like. But this lack of clarity did not stop followers from sending approximately $54,000 in donations to Wynn, as an analysis of his wallet on Arkham Intelligence showed. At least $20,000 of these funds have been sent to Hyberliquid to support another risky 40x BTC long with a liquidation price of about $103,600. At last look, Bitcoin is trading near $106,000. Arkham reported on Tuesday that this new position came within $70 of liquidation before the market rebounded, putting the high-risk trader $60,000 in profit. 'I'm trying [sic] swap inflationary fiat currency for hard capped deflationary real money at a rate of 40x leverage yet you all say I'm gambling,' Wynn said on Wednesday. 'We don't have time. Speed matters. The dollar is collapsing in real time. I'm doing everything I can to acquire as much $BTC so I don't go down with the sinking ship. What are you doing?' Read Next: A must-have for all crypto enthusiasts: . Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Image: Shutterstock This article This Bitcoin Trader Went From A $1 Billion Long Position To Begging For Donations originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
